BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33171200)

  • 21. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial.
    Hegde JV; Shaverdian N; Daly ME; Felix C; Wong DL; Rosove MH; Garst JH; Wang PC; Veruttipong D; Rao S; Fragoso RC; Riess JW; Steinberg ML; Chen AM
    Cancer; 2018 Feb; 124(3):521-529. PubMed ID: 29044458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Smoking on Outcomes of HPV-related Oropharyngeal Cancer Treated with Primary Radiation or Surgery.
    Vawda N; Banerjee RN; Debenham BJ
    Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1125-1131. PubMed ID: 30513378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Societal cost of oropharyngeal cancer by human papillomavirus status, cancer stage, and subsite.
    Silfverschiöld M; Sjövall J; Wennerberg J; Östensson E; Greiff L
    PLoS One; 2019; 14(7):e0220534. PubMed ID: 31356646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Factors for Oral Human Papillomavirus Infection Among Young Men Who Have Sex With Men-2 Cities, United States, 2012-2014.
    Oliver SE; Gorbach PM; Gratzer B; Steinau M; Collins T; Parrish A; Kerndt PR; Crosby RA; Unger ER; Markowitz LE; Meites E
    Sex Transm Dis; 2018 Oct; 45(10):660-665. PubMed ID: 30204745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insurance Status as a Predictor of Treatment in Human Papillomavirus Positive Oropharyngeal Cancer.
    Berger MH; Yasaka TM; Haidar YM; Kuan EC; Tjoa T
    Laryngoscope; 2021 Apr; 131(4):776-781. PubMed ID: 32790156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
    Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Swallowing-related outcomes associated with late lower cranial neuropathy in long-term oropharyngeal cancer survivors: cross-sectional survey analysis.
    Aggarwal P; Zaveri JS; Goepfert RP; Shi Q; Du XL; Swartz M; Lai SY; Fuller CD; Lewin JS; Piller LB; Hutcheson KA
    Head Neck; 2019 Nov; 41(11):3880-3894. PubMed ID: 31441572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy.
    Naik M; Ward MC; Bledsoe TJ; Kumar AM; Rybicki LA; Saxton JP; Burkey BB; Greskovich JF; Adelstein DJ; Koyfman SA
    Oral Oncol; 2015 Aug; 51(8):800-4. PubMed ID: 25977228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinoma.
    Yin X; Shan C; Wang J; Zhang H
    Oral Oncol; 2020 Apr; 103():104590. PubMed ID: 32050152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy.
    Caparrotti F; O'Sullivan B; Bratman SV; Ringash J; Lu L; Bayley A; Cho J; Giuliani M; Hope A; Kim J; Waldron J; Hansen A; Goldstein D; Perez-Ordonez B; Weinreb I; Tong L; Song Y; Xu W; Huang SH
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):858-867. PubMed ID: 28258893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma.
    Malm IJ; Fan CJ; Yin LX; Li DX; Koch WM; Gourin CG; Pitman KT; Richmon JD; Westra WH; Kang H; Quon H; Eisele DW; Fakhry C
    Cancer; 2017 May; 123(10):1768-1777. PubMed ID: 28055120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Risk Factors With Patient-Reported Voice and Speech Symptoms Among Long-term Survivors of Oropharyngeal Cancer.
    Aggarwal P; Hutcheson KA; Garden AS; Mott FE; Goepfert RP; Duvall A; Fuller CD; Lai SY; Gunn GB; Sturgis EM; Hanna EY; Shete S
    JAMA Otolaryngol Head Neck Surg; 2021 Jul; 147(7):615-623. PubMed ID: 33956062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competing mortality in oropharyngeal carcinoma according to human papillomavirus status.
    Lop J; García J; López M; Taberna M; Mena M; Alemany L; Quer M; León X
    Head Neck; 2019 May; 41(5):1328-1334. PubMed ID: 30549389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas.
    Ko HC; Harari PM; Sacotte RM; Chen S; Wieland AM; Yu M; Baschnagel AM; Bruce JY; Kimple RJ; Witek ME
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2341-2350. PubMed ID: 28752235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term mortality risks among patients with oropharynx cancer by human papillomavirus status.
    Fullerton ZH; Butler SS; Mahal BA; Muralidhar V; Schoenfeld JD; Tishler RB; Margalit DN
    Cancer; 2020 Apr; 126(7):1424-1433. PubMed ID: 31930488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
    Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
    Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy.
    Ihloff AS; Petersen C; Hoffmann M; Knecht R; Tribius S
    Oral Oncol; 2010 Oct; 46(10):705-11. PubMed ID: 20843732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas.
    Horne ZD; Glaser SM; Vargo JA; Ferris RL; Balasubramani GK; Clump DA; Heron DE; Beriwal S
    Cancer; 2016 Jul; 122(13):2021-30. PubMed ID: 27111669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
    Trosman SJ; Koyfman SA; Ward MC; Al-Khudari S; Nwizu T; Greskovich JF; Lamarre ED; Scharpf J; Khan MJ; Lorenz RR; Adelstein DJ; Burkey BB
    JAMA Otolaryngol Head Neck Surg; 2015 May; 141(5):457-62. PubMed ID: 25742025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.